Feasibility of Individualized Therapy for Recurrent GBM

  • STATUS
    Recruiting
  • End date
    Jan 31, 2027
  • participants needed
    30
  • sponsor
    Jennifer Clarke
Send
Updated on 1 February 2022
See if I qualify
cancer
neutrophil count
glioblastoma multiforme
gliosarcoma

Summary

The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic testing called University of California, San Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics Laboratory. The UCSF 500 Cancer Gene Panel will help identify genetic changes in the DNA of a patient's cancer, which helps oncologists improve treatment by identifying targeted therapies.

Description

This is a single arm, non-randomized open-label study to assess feasibility of implementing an individualized treatment regimen in patients with surgical recurrent GBM. Patients are not stratified according to demographic or treatment-related parameters. Patients must have recurrent glioblastoma treated with appropriate tumor treatment including radiation therapy at initial diagnosis. Surgery must be clinically indicated and patients must be candidates for tumor resection at UCSF.

The goal of the current study is to build upon prior results by confirming the feasibility of actually implementing patient-specific drug regimens in a rapid, clinically-relevant timetable. The investigators will also assess for efficacy, safety, and response outcomes of these patient-specific regimens, to generate preliminary data that would support a larger trial assessing efficacy of such an approach.

Resected tumor tissue and blood will be examined using Next Generation Sequencing (NGS) UCSF 500 Cancer Gene Panel at the UCSF Clinical Cancer Genomics Laboratory and Whole genome and RNA sequencing. The clinical report generated from the NGS UCSF 500 panel will be provided to a study-specific Tumor Board who will generate an individualized treatment recommendation based on the report. The individualized treatment regimen potentially will include up to 4 re-purposed, off-the-shelf, FDA-approved targeted agents. The Board will identify the expected/anticipated drug-drug interactions and anticipated additional toxicities of the combination of therapies. The treating physician is given the report, discusses the suggested treatment options with the patient, and initiates treatment, ideally within 28 calendar days (and no later than 35 calendar days) after surgery.

Patients may continue treatment until tumor progression, intolerable side effects, or patient/physician choice to discontinue.

Details
Condition Recurrent Glioblastoma
Treatment Individualized therapy
Clinical Study IdentifierNCT03681028
SponsorJennifer Clarke
Last Modified on1 February 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patient age must be >= 18 years
Patients must understand and provide written informed consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization authorization prior to initiation of any study-specific procedures
Patients must have recurrence of histologically-proven glioblastoma or gliosarcoma, World Health Organization (WHO) grade IV that is surgically resectable
The patient's surgeon thinks that they can resect at least 500 mg of tumor
Patient must have Karnofsky Performance Scale (KPS) score >=70
Patient must have an estimated life expectancy 3 months
Patients may enroll independent of number of prior therapies or cumulative doses of prior therapies, but must have received appropriate prior therapy for GBM at time of initial diagnosis, including radiation therapy
Patient must have adequate bone marrow function, renal function, and hepatic function as defined below
Adequate bone marrow function
absolute neutrophil count (ANC) >= 1,500/L
Platelets >= 100,000/L
Adequate hepatic function
total bilirubin <= 1.5x institutional upper limit of normal
Aspartate aminotransferase (AST) /serum glutamic-oxaloacetic transaminase (SGOT) <= 2.5x institutional upper limit of normal
Alanine aminotransferase (ALT) / serum glutamic-pyruvic transaminase (SGPT) <= 2.5x institutional upper limit of normal
Adequate renal function
creatinine <= 1.5x institutional upper limit of normal OR creatinine clearance >= 60 mL/min/1.73 m2
Must be able to undergo MRI scans for tumor evaluation
Women of child-bearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to surgery
The effects of study drugs, either individually or their combination on the
developing human fetus are unknown. For this reason, women of child-bearing
potential and men must agree to use adequate contraception prior to study
entry and for the duration of study participation and for 3 months after
completion of study drug administration. The use of adequate contraception may
be longer than 3 months depending on the drugs used and the FDA-approved
labeling in cases of recommendation for contraception. Adequate contraception
may include hormonal contraception, barrier method (condom, contraceptive
sponge, diaphragm or ring), intrauterine device (IUD), tubal ligation
vasectomy and abstinence. Should a woman become pregnant (or suspect that she
is pregnant) while she or her partner is participating in this study, she
should inform her treating physician immediately. Men treated or enrolled on
this protocol must also agree to use adequate contraception prior to the
study, for the duration of study participation, and 3 months after completion
of study drug administration. Patient must not be a woman who is currently
pregnant, due to the potential for teratogenic or abortifacient effects of
study drugs, either alone or in combination. Because there is an unknown but
potential risk of adverse events in nursing infants secondary to treatment of
the mother with study drugs, lactating women who are breastfeeding should
discontinue breastfeeding if the mother is treated with any study drug
\. Patients must not have New York Heart Association (NYHA) Grade II or
greater congestive heart failure
\. Patients must not have history of myocardial infarction or unstable
angina within 12 months prior to study enrollment

Exclusion Criteria

Patient who has been treated with any chemotherapy or radiotherapy 4 weeks prior to date of study registration. Exceptions to this include: must be 23 days from last dose of temozolomide (TMZ), must be 6 weeks from last dose of nitrosurea
Patient who has not recovered to grade 1 or baseline from the adverse effects of prior radiotherapy or chemotherapy
Patient who is < 12 weeks from initial course of radiation
Patients with multifocal tumor, primarily infratentorial or posterior fossa tumor, or leptomeningeal dissemination of tumor
Patient with any other active malignancy besides GBM, excluding non-melanomatous skin cancer, or carcinoma in situ of the cervix, prostate, or breast, unless patient has been disease-free/in remission for >=2 years prior to date of study enrollment
Patients known to be HIV-positive. HIV testing is not required for study participation
Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
neutrophil count
glioblastoma multiforme
gliosarcoma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note